Steven Scoville, MD, PhD
Links
Selected Publications
Scoville SD, Stanek JR, Rinehardt H, Sutthatam P, Abdelhafeez HA, Talbot LJ, Malek M, Leraas HJ, Tracy ET, Chen SY, Kim ES, Lopyan N, Lotakis D, Ehrlich PF, Favela J, Hau DL, Davidson J, Wilson CA, Seeman NM, Osman Y, Piche N, Hoang V, Petroze R, Polites S, Lee YM, Balagani A, Dasgupta R, McKay KG, Lovvorn HN, Aldrink JH. (2023) Comparison of outcomes between surveillance ultrasound and completion lymph node dissection in children and adolescents with sentinel lymph node positive cutaneous melanoma. Annals of Surgery. AnnSurg. 279(3):536-541.
Scoville SD, Bergus K, Diefenbach KA, Dajusta DG, Fuchs ME, Michalsky MP, Aldrink JH. Robotic-assisted surgery in patients less than 15kg: A single center review. (2024) J Laparoendosc Adv Surg Tech A. Epub ahead of print.
Wala SJ, Patterson K, Scoville S, Srinivas S, Noffsinger D, Fabia R, Thakkar RK, Schwartz DM. (2023) A single institution case series of ReCell use in treating pediatric burns. Int J Burns Trauma. 13(2):78-88.
Rajan N*, Scoville SD*, Zhang T, Miller B, Dedhia P, Phay J. (2022) Discovery of adrenal near-infrared autofluorescence. J Endocr Soc. 6(10):bvac126.
Scoville SD, Cloyd JM. (2022) Comment on: Upfront small bowel resection for SB-NETs with synchronous metastases: A proptensity-score matched comparative population-based analysis. Increasing importance in the era of Peptide recpetor radionuclide therapy. Ann Surg. 1;276(5)e631.
Lordo MR, Scoville SD, Goel A, Yu J, Freud AG, Caligiuri MA, Mundy-Bosse BL. (2021) Unraveling the role of innate lymphoid cells in acute myeloid leukemia. Cancers (Basel). 13(2):320.
Scoville SD, Cloyd JM, Pawlik TM. (2020) Treatment of neuroendocrine liver metastases: a patent landscape review. Pharm Pat Anal. 9(2):29-32
Scoville SD, Xourafas D, Ejaz AM, Tsung A, Pawlik T, Cloyd JM. (2020) Contemporary indications for and outcomes of hepatic resection for neuroendocrine liver metastases. World J Gastrointest Surg. 12(4): 159-170
Scoville SD, Cloyd JM, Pawlik TM. (2020) New and emerging systemic therapy options for well-differentiated gatroenteropancreatic neuroendocrine tumors. Expert Opin Pharmacother. 21(2):183-191.
Degrees
- The Ohio State University College of Medicine, 2018 (MD)
- The Ohio State University Wexner Medical Center, 2018 (Internship)
- The Ohio State University Wexner Medical Center, 2023 (General Surgery Residency)
- Nationwide Children’s Hospital, 2025 (Pediatric Surgery Fellowship)
Awards
- Best of the Best for Pediatric Surgery presentation finalist, 2023
- AOA Honor Society inductee, OSU, 2022
- Columbus Surgical Society’s Outstanding Resident Award, 2021
- 4th Place, OSU Department of Surgery Poster Presentation, 2021
- House Staff Teaching Award, selected among all residents by graduating medical students, 2020
- Pediatric Intern of the Year Award, Nationwide Children’s Hospital, Columbus Ohio, 2019
- Intern of the Year Award, General Surgery, OSU, 2019
Research Interests
Innate lymphoid cells (ILCs) are a family of developmentally related immune cells that have been shown to be vital for recognizing and eliminating infectious entities as well as cancer cells. In particular, Natural Killer (NK) cells are one type of ILC with the innate ability to detect cells undergoing abnormal/cancerous changes, and to destroy them, all in an antigen independent mechanism. It is well known now that cancer cells can adapt and learn to inhibit the immune system through multiple different methods. Neuroblastoma is a heterogenous solid tumor that occurs in children and can be particularly fatal in high risk disease. My lab is interested in understanding how ILCs and NK cells develop normally to better uncover the mechanisms that Neuroblastoma and other pediatric solid tumors utilize to inhibit the anti-cancer immune response. Once we can understand these mechanisms for cancer derived immune suppression we hope to develop targeted therapies that can help improve survival for the children affected by Neuroblastoma.